KR102824401B1 - S1p1 수용체와 관련된 병태의 치료 방법 - Google Patents

S1p1 수용체와 관련된 병태의 치료 방법 Download PDF

Info

Publication number
KR102824401B1
KR102824401B1 KR1020217019803A KR20217019803A KR102824401B1 KR 102824401 B1 KR102824401 B1 KR 102824401B1 KR 1020217019803 A KR1020217019803 A KR 1020217019803A KR 20217019803 A KR20217019803 A KR 20217019803A KR 102824401 B1 KR102824401 B1 KR 102824401B1
Authority
KR
South Korea
Prior art keywords
delete delete
compound
subject
treatment
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217019803A
Other languages
English (en)
Korean (ko)
Other versions
KR20210098487A (ko
Inventor
스니할 나이크
Original Assignee
아레나 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아레나 파마슈티칼스, 인크. filed Critical 아레나 파마슈티칼스, 인크.
Publication of KR20210098487A publication Critical patent/KR20210098487A/ko
Application granted granted Critical
Publication of KR102824401B1 publication Critical patent/KR102824401B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020217019803A 2018-11-30 2019-11-26 S1p1 수용체와 관련된 병태의 치료 방법 Active KR102824401B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862773936P 2018-11-30 2018-11-30
US62/773,936 2018-11-30
US201962850464P 2019-05-20 2019-05-20
US62/850,464 2019-05-20
PCT/US2019/063413 WO2020112880A1 (en) 2018-11-30 2019-11-26 Methods of treating conditions related to the s1p1 receptor

Publications (2)

Publication Number Publication Date
KR20210098487A KR20210098487A (ko) 2021-08-10
KR102824401B1 true KR102824401B1 (ko) 2025-06-25

Family

ID=68966033

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217019803A Active KR102824401B1 (ko) 2018-11-30 2019-11-26 S1p1 수용체와 관련된 병태의 치료 방법

Country Status (9)

Country Link
US (1) US20220023258A1 (cg-RX-API-DMAC7.html)
EP (1) EP3886841A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022511788A (cg-RX-API-DMAC7.html)
KR (1) KR102824401B1 (cg-RX-API-DMAC7.html)
CN (2) CN118649163A (cg-RX-API-DMAC7.html)
AU (1) AU2019387212A1 (cg-RX-API-DMAC7.html)
CA (1) CA3120706A1 (cg-RX-API-DMAC7.html)
IL (1) IL283414A (cg-RX-API-DMAC7.html)
WO (1) WO2020112880A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2528894A1 (en) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CA3002540C (en) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ, インコーポレイテッド S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩
KR20190113955A (ko) 2017-02-16 2019-10-08 아레나 파마슈티칼스, 인크. 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ, インコーポレイテッド S1p1受容体に関連する状態を治療する方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018531936A (ja) * 2015-09-30 2018-11-01 ノグラ ファーマ リミテッド バイオマーカー発現に基づいてsmad7アンチセンスオリゴヌクレオチドを使用する方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104311472B9 (zh) * 2008-07-23 2020-03-17 艾尼纳制药公司 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物
EP2528894A1 (en) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
WO2013116657A1 (en) * 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
RU2016147569A (ru) * 2014-05-09 2018-06-13 Ногра Фарма Лимитед Способы лечения воспалительного заболевания кишечника
CA3002540C (en) * 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
CN110520124A (zh) * 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018531936A (ja) * 2015-09-30 2018-11-01 ノグラ ファーマ リミテッド バイオマーカー発現に基づいてsmad7アンチセンスオリゴヌクレオチドを使用する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mihaela Dranga et al., Turk J Gastroenterol., 2016, Vol. 27, pp 149-155. 1부.*

Also Published As

Publication number Publication date
CA3120706A1 (en) 2020-06-04
CN113226307A (zh) 2021-08-06
KR20210098487A (ko) 2021-08-10
EP3886841A1 (en) 2021-10-06
JP2025024035A (ja) 2025-02-19
AU2019387212A1 (en) 2021-06-24
IL283414A (en) 2021-07-29
WO2020112880A1 (en) 2020-06-04
US20220023258A1 (en) 2022-01-27
CN118649163A (zh) 2024-09-17
JP2022511788A (ja) 2022-02-01

Similar Documents

Publication Publication Date Title
AU2021200129B2 (en) Methods of treating conditions related to the S1P1 receptor
KR102958419B1 (ko) S1p₁ 수용체와 관련된 병태의 치료 방법
US20220023258A1 (en) Methods of treating conditions related to the s1p1 receptor
EP3801459B1 (en) Methods of treating conditions related to the s1p1 receptor
HK40116488A (en) Methods of treating conditions related to the s1p1 receptor
HK40111393A (en) Compound for use in treating conditions related to the s1p1 receptor
HK40050237B (en) Methods of treating conditions related to the s1p1 receptor
HK40050237A (en) Methods of treating conditions related to the s1p1 receptor
HK40063670A (en) Methods of treating conditions related to the s1p1 receptor
HK1240134B (en) Compound for use in treating conditions related to the s1p1 receptor
HK1240134A1 (en) Compound for use in treating conditions related to the s1p1 receptor
JP2023548475A (ja) S1p1受容体に関係する病態を治療する方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210625

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20221123

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240816

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250422

PG1601 Publication of registration